| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8827960 | European Urology Focus | 2017 | 8 Pages |
Abstract
Upper tract urothelial carcinoma is often associated with poor clinical outcome. While current treatment options for advanced upper tract urothelial carcinoma are limited, programmed death-ligand 1 positivity in approximately one-third of invasive tumors provides a rational basis for further investigation of programmed death-ligand 1-based immunotherapeutics in these patients.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Stephanie L. Skala, Tzu-Ying Liu, Aaron M. Udager, Alon Z. Weizer, Jeffrey S. Montgomery, Ganesh S. Palapattu, Javed Siddiqui, Xuhong Cao, Kristina Fields, Ahmed E. Abugharib, Moaaz Soliman, Khaled S. Hafez, David Miller, Cheryl T. Lee, Ajjai Alva,